AXGN analyst estimates
Axogen (AXGN) analyst ratings, the average price target and its range, and every firm's latest call.
AXGN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Raymond James | AxoGen, Inc. (AXGN) PT Raised to $57 at Raymond James | $57.00 |
| Oct 29, 2026 | Barclays | AxoGen price target raised to $60 from $50 at Barclays | $60.00 |
| Oct 29, 2026 | H.C. Wainwright | AxoGen price target raised to $56 from $53 at H.C. Wainwright | $56.00 |
| Oct 29, 2026 | Lake Street | AxoGen price target raised to $58 from $55 at Lake Street | $58.00 |
| Oct 29, 2026 | Leerink Partners | AxoGen price target raised to $56 from $52 at Leerink | $56.00 |
| Oct 28, 2026 | Mizuho Securities | AxoGen, Inc. (AXGN) PT Raised to $65 at Mizuho | $65.00 |
| Oct 28, 2026 | Jefferies | AxoGen price target raised to $60 from $55 at Jefferies | $60.00 |
| Oct 23, 2026 | Barclays | AxoGen price target lowered to $50 from $55 at Barclays | $50.00 |
| Oct 6, 2026 | Barclays | AxoGen initiated with an Overweight at Barclays | $55.00 |
| Oct 1, 2026 | Truist Financial | AxoGen, Inc. (AXGN) PT Lowered to $53 at Truist Securities | $53.00 |
| Sep 25, 2026 | Raymond James | AxoGen, Inc. (AXGN) PT Raised to $53 at Raymond James | $53.00 |
| Aug 26, 2026 | Truist Financial | AxoGen initiated with a Buy at Truist | $60.00 |
| Jul 30, 2026 | Truist Financial | AxoGen, Inc. (AXGN) PT Raised to $55 at Citizens on Q2 Performance | $55.00 |
| Jul 30, 2026 | H.C. Wainwright | AxoGen, Inc. (AXGN) PT Raised to $53 at H.C. Wainwright | $53.00 |
| Jul 29, 2026 | Jefferies | AxoGen price target raised to $55 from $50 at Jefferies | $55.00 |
- 12 firms rate AXGN: 12 buy, 0 hold, 0 sell.
- The average price target is $58.12 from 8 analysts, from $53.00 to $65.00.
Updated 2026-11-02 23:59 UTC